19 May 2026
Pharmaceuticals | Top 5 Selected Papers in 2024–2025 in the “Medicinal Chemistry” Section
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
1. “A Comprehensive Review on Deep Eutectic Solvents and Its Use to Extract Bioactive Compounds of Pharmaceutical Interest”
by Cátia Ferreira and Mafalda Sarraguça
Pharmaceuticals 2024, 17(1), 124; https://doi.org/10.3390/ph17010124
Available online: https://www.mdpi.com/1424-8247/17/1/124
2. “Discovery of Dual TRPA1 and TRPV1 Antagonists as Novel Therapeutic Agents for Pain”
by Nayeon Do, Dongxu Zuo, Miri Kim, Minseok Kim, Hee-Jin Ha, Peter M. Blumberg, Jihyae Ann, Sun Wook Hwang and Jeewoo Lee
Pharmaceuticals 2024, 17(9), 1209; https://doi.org/10.3390/ph17091209
Available online: https://www.mdpi.com/1424-8247/17/9/1209
3. “Study of the Lipophilicity and ADMET Parameters of New Anticancer Diquinothiazines with Pharmacophore Substituents”
by Daria Klimoszek, Małgorzata Jeleń, Małgorzata Dołowy and Beata Morak-Młodawska
Pharmaceuticals 2024, 17(6), 725; https://doi.org/10.3390/ph17060725
Available online: https://www.mdpi.com/1424-8247/17/6/725
4. “The Potential of Artificial Intelligence in Pharmaceutical Innovation: From Drug Discovery to Clinical Trials”
by Vera Malheiro, Beatriz Santos, Ana Figueiras and Filipa Mascarenhas-Melo
Pharmaceuticals 2025, 18(6), 788; https://doi.org/10.3390/ph18060788
Available online: https://www.mdpi.com/1424-8247/18/6/788
5. “Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer’s Disease”
by Melinda Urkon, Elek Ferencz, József Attila Szász, Monica Iudita Maria Szabo, Károly Orbán-Kis, Szabolcs Szatmári and Előd Ernő Nagy
Pharmaceuticals 2025, 18(5), 614; https://doi.org/10.3390/ph18050614
Available online: https://www.mdpi.com/1424-8247/18/5/614